The General Hospital Corporation

Ardelyx, Inc.

Novabay Pharmaceuticals, Inc.

Novartis Ag

Massachusetts Institute of Technology

Vicuron Pharmaceuticals Inc.

Pfizer Corporation

Sandoz Gmbh

Vicuron Holdings LLC

Xtuit Pharmaceuticals, Inc.

Massachusetts General Hospital Corporation

Gottardi, Waldemar

Nagl, Markus

Rakesh K Jain

Jason Gustaf Lewis

Charles Francavilla

Jeremy Caldwell

Jeffrey William Jacobs

Zhengyu Yuan

Timothy Shiau

Eddy Low

Dai Fukumura

Helene Baribault

Jianhua Chao

Lily Hu

Tao Chen

Michael Robert Leadbetter

Dinesh Vinoobhai Patel

Dean R Dragoli

Noah Bell

Patricia Finn

Satheesh K Nair

Eric Douglas Turtle

Mohindra Seepersaud

Donogh John Roger O'Mahony

Matthew John Siegel

Igor Garkavtsev

Lei Shu

Paolo Netti

Robert J Melder

Ralston Curtis

Simon Bushell

Arathi Sundaram

William L Fitch

David C Creech

Kathryn Rene Bracken

Karl Dean

Kwangho Lee

Lance L Munn

Robert Samuel Langer

Moungi G Bawendi

Brian Seed

Donald E Chickering, Iii

Mikhail Fedorovich Gordeev

Lawrence Alan Reiter

Zhi-Jie Ni

Richard Hardwick Moore

Alan Crane

Daniel B Kopans

Ramin Najafi

Matthew Siegel

Jason G Lewis

Cliff Richard Wong

Lucian Gheorghe Gruionu

Gabriel Gruionu

Qing Sheng

Rong Tong

Peter Blume-Jensen

Keehoon Jung

Vasileios Askoxylakis

Gino B Ferraro

David P Kodack

Dan G Duda

Sergey V Kozin

Bum Kim

Paul W Kopesky

Vikash Pal Singh Chauhan

Joao Incio

Robert B Campbell

Gabriel Helmlinger

Hera Lichtenbeld-Dubois

Gerald C Koenig

Yves Boucher

Adam Stacy-Clear

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L, A, X, X, R, R, and Rare described herein.

Hormone receptor modulators for treating metabolic conditions and disorders

The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula:

Substituted 4-phenyl pyridine compounds as non-systemic TGR5 agonists

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L, L, A, B, R, R, R, and Rare described herein.

Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators

Provided herein are polymers, pH-sensitive polymers and/or linkers; conjugates comprising said polymers and/or linkers, optionally, coupled to one or more agents and/or targeting moieties; and particles (e.g., nanoparticles comprising the aforesaid polymers, linkers and/or conjugates), which can be used to enhance the delivery and/or efficacy of one or more agents in a subject.

Polyacetal polymers, conjugates, particles and uses thereof

This invention relates to antagonists of G3BP2, G3BP1, and ZEB1. Pharmaceutical compositions comprising G3BP2 inhibitors, methods of inhibiting G3BP2, G3BP1, and ZEB1, methods of treating cancer and inflammation, and methods of identifying an inhibitor of cancer stems cells are also provided.

Compounds for targeting cancer stem cells

This invention relates to compounds that are useful for inhibiting the secretion of secretory leukocyte protease inhibitor (SLPI) in a subject. Methods of inhibiting metastasis of cancer and methods of treating cancer in a subject are also provided.

Compounds for inhibiting secretory leukocyte protease inhibitor (SLPI)

Agents that inhibit CX3CL1 in endothelial cells to reduce or inhibit immunosuppression mechanisms that are co-opted by cancer cells to evade host immune system, and that reduce immunosuppression in context of therapies that target VEGF-dependent signaling, and methods of use thereof.

Compositions and methods to improve anti-angiogenic therapy and immunotherapy

A system and method is configured for use with an endoscope, a biopsy needle, and a data acquisition system. The system includes a sensor tip and a pressure sensor coupled to the sensor tip and having at least one piezo-resistor component with an internal-facing side and an external-facing side, and an opening adjacent to the at least one piezo-resistor component to allow fluid access to the internal-facing side and the external-facing side. The system also includes a tubing member with a distal end and a proximal end, the sensor tip coupled to the distal end, the sensor tip and the tubing member configured to be routed through the biopsy needle and connection elements coupled to the proximal end of the tubing member, the connection elements configured to mount the tubing member relative to the biopsy needle and to couple the pressure sensor to the data acquisition system.

System and method for measuring solid stress in tissues

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L, L, A, B, R, R, R, and Rare described herein. 

The invention relates to non-systemic TGR5 agonist useful in the treatment of chemotherapy-induced diarrhea, diabetes, Type II diabetes, gestational diabetes, impaired fasting glucose, impaired glucose tolerance, insulin resistance, hyperglycemia, obesity, metabolic syndrome, ulcerative colitis, Crohn's disease, disorders associated with parenteral nutrition especially during short bowel syndrome, and irritable bowel syndrome (IBS), and other TGR5 associated diseases and disorders, having the Formula: where R, R, R, R, R, X, X, X, X, Q, and n are described herein.

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L, A, X, X, R, R, and Rare described herein. 

The present invention relates to a pharmaceutical combination which comprises (a) a phosphatidylinositol 3-kinase inhibitor or pharmaceutically acceptable salt thereof, and (b) a Her3 antagonist, for simultaneous, separate or sequential administration for the treatment of breast cancer brain metastases; a method of treating a subject having a breast cancer brain metastases comprising administration of said combination to a subject in need thereof; use of such combination for the treatment of breast cancer brain metastases; and a commercial package comprising such combination.

Treatment of breast cancer brain metastases

Nanoparticles for a selective, two stage delivery to tumors have been developed. The nanoparticles are initially sized so that they preferentially accumulate in the tumor tissue as a result of leakage through the defective vascular in the solid tumors. Once in the tumor tissue, the nanoparticles are cleaved hydrolytically and/or by enzymatic cleavage over time to release smaller nanoparticles carrying therapeutic, prophylactic or diagnostic agents into the necrotic interior of the tumors. This provides a simple, elegant and highly effective means of delivery drug selectively not just to tumors generally, but, more importantly, into the poorly vascularized necrotic interiors which drugs are normally unable to penetrate. The nanoparticles have a number of advantages: less toxicity due to selective accumulation only in the tumors; access into the poorly vascularized necrotic interiors of the tumor; and sustained release over a period of time within the tumor.

Multistage nanoparticle drug delivery system for the treatment of solid tumors

The present application describes compounds of Formula I: which are antimicrobial agents, including antibacterial, disinfectant, antifungal, germicidal and/or antiviral agents.

Substituted N,N-dihaloamines as antimicrobials

Growing community of inventors

Wellesley, MA, United States of America

Rakesh K Jain